Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

Journal of Viral Hepatitis

Volumn 21, Issue 5, 2014, Pages 357-365

  Harada, N ^a   Hiramatsu, N ^a   Oze, T ^a   Morishita, N ^a   Yamada, R ^a   Hikita, H ^a   Miyazaki, M ^a   Yakushijin, T ^a   Miyagi, T ^a   Yoshida, Y ^a   Tatsumi, T ^a   Kanto, T ^a   Kasahara, A ^a   Oshita, M ^b   Mita, E ^c   Hagiwara, H ^d   Inui, Y ^e   Katayama, K ^f   Tamura, S ^g   Yoshihara, H ^h   Imai, Y ⁱ   Inoue, A ^j   Hayashi, N ^d   Takehara, T ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e Hyogo Prefectural Nishinomiya Hospital   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g Minoh City Hospital   (Japan)

^h OSAKA ROSAI HOSPITAL   (Japan)

ⁱ Ikeda Municipal Hospital   (Japan)

^j OSAKA GENERAL MEDICAL CENTER   (Japan)

more..

Author keywords

hepatitis C; hepatocellular carcinoma; normal alanine aminotransferase levels; Peg IFN plus ribavirin combination therapy; persistent normal alanine aminotransferase levels

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HAZARD RATIO; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER ANGIOGRAPHY; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; HEPATITIS C, CHRONIC; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS;

EID: 84898478190     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12151     Document Type: Article

References (24)

1. Sangiovanni A, Morales R, Spinzi G, et al,. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27 (3): 853-856.
2. Pradat P, Alberti A, Poynard T, et al,. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36 (4 Pt 1): 973-977.
3. Tassopoulos NC,. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31 (Suppl 1): 193-196.
4. Zeuzem S, Diago M, Gane E, et al,. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127 (6): 1724-1732.
5. Hiramatsu N, Inoue Y, Oze T, et al,. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. J Gastroenterol 2011; 46 (11): 1335-1343.
6. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295 (1): 65-73.
7. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999; 31 (Suppl 1): 3-8.
8. Strader DB, Wright T, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39 (4): 1147-1171.
9. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-293.
10. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123 (6): 2082-2099.
11. Fattovich G, Giustina G, Degos F, et al,. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463-472.
12. Persico M, Persico E, Suozzo R, et al,. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118 (4): 760-764.
13. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al,. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34 (5): 1000-1005.
14. Deuffic-Burban S, Babany G, Lonjon-Domanec I, et al,. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009; 50 (5): 1351-1359.
15. Alberti A, Chemello L, Benvegnu L,. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1): 17-24.
16. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832.
17. Kurokawa M, Hiramatsu N, Oze T, et al,. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009; 39 (5): 432-438.
18. Roffi L, Redaelli A, Colloredo G, et al,. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol 2001; 13 (5): 501-506.
19. Hatzakis A, Katsoulidou A, Kaklamani E, et al,. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996; 68 (1): 51-53.
20. Harada N, Hiramatsu N, Oze T, et al,. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. J Gastroenterol 2013; 48 (4): 535-543.
21. Asahina Y, Tsuchiya K, Tamaki N, et al,. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52 (2): 518-527.
22. Isokawa O, Suda T, Aoyagi Y, et al,. Reduction of telomeric repeats as a possible predictor for development of hepatocellular carcinoma: convenient evaluation by slot-blot analysis. Hepatology 1999; 30 (2): 408-412.
23. Hoare M, Das T, Alexander G,. Ageing, telomeres, senescence, and liver injury. J Hepatol 2010; 53 (5): 950-961.
24. Ikeda K, Saitoh S, Arase Y, et al,. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29 (4): 1124-1130.